Stepping out of the shadows: Oncogenic and tumor-promoting protein tyrosine phosphatases.

[1]  N. Bottini,et al.  Targeting Tyrosine Phosphatases: Time to End the Stigma. , 2017, Trends in pharmacological sciences.

[2]  Monia Magliozzi,et al.  Structural, Functional, and Clinical Characterization of a Novel PTPN11 Mutation Cluster Underlying Noonan Syndrome , 2017, Human mutation.

[3]  Hu Li,et al.  Critical Role for GAB2 in Neuroblastoma Pathogenesis through the Promotion of SHP2/MYCN Cooperation. , 2017, Cell reports.

[4]  T. Barth,et al.  A novel PTPN1 splice variant upregulates JAK/STAT activity in classical Hodgkin lymphoma cells. , 2017, Blood.

[5]  M. Kramer,et al.  The PTPROt tyrosine phosphatase functions as an obligate haploinsufficient tumor suppressor in vivo in B-cell chronic lymphocytic leukemia , 2017, Oncogene.

[6]  Julia Müller,et al.  The protein‐tyrosine phosphatase DEP‐1 promotes migration and phagocytic activity of microglial cells in part through negative regulation of fyn tyrosine kinase , 2017, Glia.

[7]  D. Beis,et al.  Pleiotrophin and its receptor protein tyrosine phosphatase beta/zeta as regulators of angiogenesis and cancer. , 2016, Biochimica et biophysica acta.

[8]  Jian Huang,et al.  Cell Transformation by PTP1B Truncated Mutants Found in Human Colon and Thyroid Tumors , 2016, PloS one.

[9]  Kuen-Feng Chen,et al.  Corrigendum: Protein tyrosine phosphatase 1B targets PITX1/p120RasGAP thus showing therapeutic potential in colorectal carcinoma , 2016, Scientific Reports.

[10]  T. Olender,et al.  Regulation of receptor-type protein tyrosine phosphatases by their C-terminal tail domains. , 2016, Biochemical Society transactions.

[11]  T. Cai,et al.  Small cell lung cancer growth is inhibited by miR-342 through its effect of the target gene IA-2 , 2016, Journal of Translational Medicine.

[12]  A. Fusco,et al.  Tyrosine Phosphatase PTPRJ/DEP-1 Is an Essential Promoter of Vascular Permeability, Angiogenesis, and Tumor Progression. , 2016, Cancer research.

[13]  Y. Liu,et al.  PTPH1 promotes tumor growth and metastasis in human glioma. , 2016, European review for medical and pharmacological sciences.

[14]  M. Paquet,et al.  SHP-2 phosphatase contributes to KRAS-driven intestinal oncogenesis but prevents colitis-associated cancer development , 2016, Oncotarget.

[15]  X. Bian,et al.  PTP1B promotes aggressiveness of breast cancer cells by regulating PTEN but not EMT , 2016, Tumor Biology.

[16]  Kuen-Feng Chen,et al.  Protein tyrosine phosphatase 1B dephosphorylates PITX1 and regulates p120RasGAP in hepatocellular carcinoma , 2016, Hepatology.

[17]  B. Neel,et al.  Distinct GAB2 signaling pathways are essential for myeloid and lymphoid transformation and leukemogenesis by BCR-ABL1. , 2016, Blood.

[18]  P. Kuppen,et al.  Increased PTP1B expression and phosphatase activity in colorectal cancer results in a more invasive phenotype and worse patient outcome , 2016, Oncotarget.

[19]  N. Hockstein,et al.  CD45 Phosphatase Inhibits STAT3 Transcription Factor Activity in Myeloid Cells and Promotes Tumor-Associated Macrophage Differentiation. , 2016, Immunity.

[20]  B. Neel,et al.  Gain-of-function mutations of Ptpn11 (Shp2) cause aberrant mitosis and increase susceptibility to DNA damage-induced malignancies , 2016, Proceedings of the National Academy of Sciences.

[21]  Y. Agazie,et al.  SHP2 acts both upstream and downstream of multiple receptor tyrosine kinases to promote basal-like and triple-negative breast cancer , 2016, Breast Cancer Research.

[22]  A. Zarbock,et al.  Interfering with VE-PTP stabilizes endothelial junctions in vivo via Tie-2 in the absence of VE-cadherin , 2015, The Journal of experimental medicine.

[23]  M. Summar,et al.  Malignancy in Noonan syndrome and related disorders , 2015, Clinical genetics.

[24]  A. Godwin,et al.  PTN signaling: Components and mechanistic insights in human ovarian cancer , 2015, Molecular carcinogenesis.

[25]  S. Tavazoie,et al.  PTPRN2 and PLCβ1 promote metastatic breast cancer cell migration through PI(4,5)P2‐dependent actin remodeling , 2015, The EMBO journal.

[26]  B. Raught,et al.  Inhibition of SHP2-mediated dephosphorylation of Ras suppresses oncogenesis , 2015, Nature Communications.

[27]  Zhon-Yin Zhang,et al.  Protein Tyrosine Phosphatases in Hypothalamic Insulin and Leptin Signaling. , 2015, Trends in pharmacological sciences.

[28]  Q. Gao,et al.  Expression and clinical significance of tyrosine phosphatase SHP2 in thyroid carcinoma. , 2015, Oncology letters.

[29]  Paul Delmar,et al.  PTPRF Expression as a Potential Prognostic/Predictive Marker for Treatment with Erlotinib in Non–Small-Cell Lung Cancer , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[30]  T. Betsuyaku,et al.  Prognostic implication of PTPRH hypomethylation in non-small cell lung cancer , 2015, Oncology reports.

[31]  B. Györffy,et al.  Shp2 signaling suppresses senescence in PyMT‐induced mammary gland cancer in mice , 2015, The EMBO journal.

[32]  M. Hung,et al.  Aberrant Expression of proPTPRN2 in Cancer Cells Confers Resistance to Apoptosis. , 2015, Cancer research.

[33]  Yan-wen Yao,et al.  PTP1B promotes cell proliferation and metastasis through activating src and ERK1/2 in non-small cell lung cancer. , 2015, Cancer letters.

[34]  Kathleen M Spring,et al.  The protein tyrosine phosphatase DEP-1/PTPRJ promotes breast cancer cell invasion and metastasis , 2015, Oncogene.

[35]  P. Campochiaro,et al.  Treatment of diabetic macular edema with an inhibitor of vascular endothelial-protein tyrosine phosphatase that activates Tie2. , 2015, Ophthalmology.

[36]  O. Abdel-Wahab,et al.  Mutated Ptpn11 alters leukemic stem cell frequency and reduces the sensitivity of acute myeloid leukemia cells to Mcl1 inhibition , 2014, Leukemia.

[37]  Wei Liu,et al.  Frequent amplification of PTP1B is associated with poor survival of gastric cancer patients , 2015, Cell cycle.

[38]  P. Campochiaro,et al.  Targeting VE-PTP activates TIE2 and stabilizes the ocular vasculature. , 2014, The Journal of clinical investigation.

[39]  S. Brady-Kalnay,et al.  A Protease Storm Cleaves a Cell–Cell Adhesion Molecule in Cancer: Multiple Proteases Converge to Regulate PTPmu in Glioma Cells , 2014, Journal of cellular biochemistry.

[40]  P. Wesseling,et al.  Intracellular and extracellular domains of protein tyrosine phosphatase PTPRZ-B differentially regulate glioma cell growth and motility , 2014, Oncotarget.

[41]  Z. Xiong,et al.  Knockdown of protein tyrosine phosphatase receptor U inhibits growth and motility of gastric cancer cells. , 2014, International journal of clinical and experimental pathology.

[42]  Hualiang Jiang,et al.  Protein tyrosine phosphatase receptor U (PTPRU) is required for glioma growth and motility. , 2014, Carcinogenesis.

[43]  Kathleen M Spring,et al.  Phosphorylation of DEP-1/PTPRJ on threonine 1318 regulates Src activation and endothelial cell permeability induced by vascular endothelial growth factor. , 2014, Cellular signalling.

[44]  Xianghuo He,et al.  Activating mutations in PTPN3 promote cholangiocarcinoma cell proliferation and migration and are associated with tumor recurrence in patients. , 2014, Gastroenterology.

[45]  M. Stratton,et al.  Recurrent PTPRB and PLCG1 mutations in angiosarcoma , 2014, Nature Genetics.

[46]  E. Pai,et al.  Structural insights into Noonan/LEOPARD syndrome-related mutants of protein-tyrosine phosphatase SHP2 (PTPN11) , 2014, BMC Structural Biology.

[47]  D. Vestweber,et al.  Phosphatases and kinases as regulators of the endothelial barrier function , 2014, Cell and Tissue Research.

[48]  T. Han,et al.  SHP2 promotes laryngeal cancer growth through the Ras/Raf/Mek/Erk pathway and serves as a prognostic indicator for laryngeal cancer. , 2014, International journal of oncology.

[49]  H. Brinkhaus,et al.  Tyrosine phosphatase PTPα contributes to HER2-evoked breast tumor initiation and maintenance , 2014, Oncogene.

[50]  M. Mason,et al.  Receptor-like protein tyrosine phosphatase κ negatively regulates the apoptosis of prostate cancer cells via the JNK pathway. , 2013, International journal of oncology.

[51]  D. Miranda-Saavedra,et al.  PTP1B: A simple enzyme for a complex world , 2013, Critical reviews in biochemistry and molecular biology.

[52]  R. Jain,et al.  Effects of vascular-endothelial protein tyrosine phosphatase inhibition on breast cancer vasculature and metastatic progression. , 2013, Journal of the National Cancer Institute.

[53]  Michael A. Freitas,et al.  Methylation of the PTPRO gene in human hepatocellular carcinoma and identification of VCP as its substrate , 2013, Journal of cellular biochemistry.

[54]  F. Gao,et al.  Src homology phosphotyrosyl phosphatase‐2 expression is an independent negative prognostic factor in human breast cancer , 2013, Histopathology.

[55]  M. Mehler,et al.  Receptor-type Protein-tyrosine Phosphatase ζ Is a Functional Receptor for Interleukin-34* , 2013, The Journal of Biological Chemistry.

[56]  L. Rönnstrand,et al.  Deregulation of protein phosphatase expression in acute myeloid leukemia , 2013, Medical Oncology.

[57]  N. Tonks.  Protein Tyrosine Phosphatases: From Housekeeping Enzymes to Master-Regulators of Signal Transduction , 2013 .

[58]  R. Pulido,et al.  Protein tyrosine phosphatases in health and disease , 2013, The FEBS journal.

[59]  M. Kojima,et al.  PTPRZ1 regulates calmodulin phosphorylation and tumor progression in small-cell lung carcinoma , 2012, BMC Cancer.

[60]  K. Bence,et al.  Central Regulation of Metabolism by Protein Tyrosine Phosphatases , 2012, Front. Neurosci..

[61]  J. Courty,et al.  Loss of Receptor Protein Tyrosine Phosphatase β/ζ (RPTPβ/ζ) Promotes Prostate Cancer Metastasis* , 2012, The Journal of Biological Chemistry.

[62]  Kathleen M Spring,et al.  Tyrosine phosphorylation of DEP-1/CD148 as a mechanism controlling Src kinase activation, endothelial cell permeability, invasion, and capillary formation. , 2012, Blood.

[63]  C. Lim,et al.  Protein Tyrosine Phosphatase α Phosphotyrosyl-789 Binds BCAR3 To Position Cas for Activation at Integrin-Mediated Focal Adhesions , 2012, Molecular and Cellular Biology.

[64]  A. Sloan,et al.  Protein tyrosine phosphatase mu regulates glioblastoma cell growth and survival in vivo. , 2012, Neuro-oncology.

[65]  L. Lessard,et al.  PTP1B is an androgen receptor-regulated phosphatase that promotes the progression of prostate cancer. , 2012, Cancer research.

[66]  Stephen J. Elledge,et al.  Tyrosine phosphatase SHP2 promotes breast cancer progression and maintains tumor-initiating cells via activation of key transcription factors and a positive feedback signaling loop , 2012, Nature Medicine.

[67]  E. Kasper,et al.  Src homology domain-containing phosphatase 2 suppresses cellular senescence in glioblastoma , 2011, British Journal of Cancer.

[68]  Cai-yun Zhou,et al.  Significance of PTPRZ1 and CIN85 expression in cervical carcinoma , 2011, Archives of Gynecology and Obstetrics.

[69]  B. Neel,et al.  Epithelial Protein-Tyrosine Phosphatase 1B Contributes to the Induction of Mammary Tumors by HER2/Neu but Is Not Essential for Tumor Maintenance , 2011, Molecular Cancer Research.

[70]  A. Knudson,et al.  A continuum model for tumour suppression , 2011, Nature.

[71]  D. Shalloway,et al.  Activation of Src and transformation by an RPTPα splice mutant found in human tumours , 2011, The EMBO journal.

[72]  T. Cotter,et al.  Inhibition of Protein-tyrosine Phosphatase 1B (PTP1B) Mediates Ubiquitination and Degradation of Bcr-Abl Protein* , 2011, The Journal of Biological Chemistry.

[73]  O. Rozenblatt-Rosen,et al.  SHP2 tyrosine phosphatase converts parafibromin/Cdc73 from a tumor suppressor to an oncogenic driver. , 2011, Molecular cell.

[74]  Rong-shan Li,et al.  PTPH1 cooperates with vitamin D receptor to stimulate breast cancer growth through their mutual stabilization , 2010, Oncogene.

[75]  G. Martinelli,et al.  Protein tyrosine phosphatase receptor type {gamma} is a functional tumor suppressor gene specifically downregulated in chronic myeloid leukemia. , 2010, Cancer research.

[76]  Rudolph L. Leibel,et al.  Obesity and leptin resistance: distinguishing cause from effect , 2010, Trends in Endocrinology & Metabolism.

[77]  L. Insabato,et al.  PTPD1 Supports Receptor Stability and Mitogenic Signaling in Bladder Cancer Cells* , 2010, The Journal of Biological Chemistry.

[78]  Zchong‐Zcho Wu,et al.  Identification and functional analysis of genes which confer resistance to cisplatin in tumor cells. , 2010, Biochemical pharmacology.

[79]  D. Shalloway,et al.  Extracellular domain dependence of PTPα transforming activity , 2010, Genes to cells : devoted to molecular & cellular mechanisms.

[80]  F. Oswald,et al.  Substrate stiffness and the receptor-type tyrosine-protein phosphatase alpha regulate spreading of colon cancer cells through cytoskeletal contractility , 2010, Oncogene.

[81]  J. den Hertog,et al.  Serine Dephosphorylation of Receptor Protein Tyrosine Phosphatase α in Mitosis Induces Src Binding and Activation , 2010, Molecular and Cellular Biology.

[82]  Rong-shan Li,et al.  PTPH1 dephosphorylates and cooperates with p38gamma MAPK to increase ras oncogenesis through PDZ-mediated interaction. , 2010, Cancer research.

[83]  L. Lessard,et al.  The two faces of PTP1B in cancer. , 2010, Biochimica et biophysica acta.

[84]  L. Caromile,et al.  The Neurosecretory Vesicle Protein Phogrin Functions as a Phosphatidylinositol Phosphatase to Regulate Insulin Secretion* , 2010, The Journal of Biological Chemistry.

[85]  Y. Refaeli,et al.  TC-PTP is required for the maintenance of MYC-driven B-cell lymphomas. , 2009, Blood.

[86]  A. Bennett,et al.  Physiological signaling specificity by protein tyrosine phosphatases. , 2009, Physiology.

[87]  A. Sloan,et al.  Proteolytic cleavage of protein tyrosine phosphatase mu regulates glioblastoma cell migration. , 2009, Cancer research.

[88]  Luis E. Arias-Romero,et al.  Activation of Src by protein tyrosine phosphatase 1B Is required for ErbB2 transformation of human breast epithelial cells. , 2009, Cancer research.

[89]  A. Harada,et al.  SAP‐1 is a microvillus‐specific protein tyrosine phosphatase that modulates intestinal tumorigenesis , 2009, Genes to cells : devoted to molecular & cellular mechanisms.

[90]  Yan P. Yuan,et al.  Frameshift mutations in coding repeats of protein tyrosine phosphatase genes in colorectal tumors with microsatellite instability , 2008, BMC Cancer.

[91]  Y. Agazie,et al.  SHP2 is up‐regulated in breast cancer cells and in infiltrating ductal carcinoma of the breast, implying its involvement in breast oncogenesis , 2008, Histopathology.

[92]  S. Kondo,et al.  Isolation of a distinct class of gain-of-function SHP-2 mutants with oncogenic RAS-like transforming activity from solid tumors , 2008, Oncogene.

[93]  D. Shalloway,et al.  Apoptosis of estrogen‐receptor negative breast cancer and colon cancer cell lines by PTPα and src RNAi , 2008, International journal of cancer.

[94]  A. Östman,et al.  Protein tyrosine phosphatases: regulatory mechanisms , 2008 .

[95]  B. Neel,et al.  The tyrosine phosphatase Shp2 (PTPN11) in cancer , 2008, Cancer and Metastasis Reviews.

[96]  O. Abaan,et al.  PTPL1: a large phosphatase with a split personality , 2008, Cancer and Metastasis Reviews.

[97]  J. Bjorge,et al.  PTP1B contributes to the oncogenic properties of colon cancer cells through Src activation. , 2007, Cancer research.

[98]  B. Walzog,et al.  Inhibition of the Tyrosine Phosphatase SHP-2 Suppresses Angiogenesis in vitro and in vivo , 2007, Journal of Vascular Research.

[99]  A. Elson,et al.  Neu-mediated phosphorylation of protein tyrosine phosphatase epsilon is critical for activation of Src in mammary tumor cells , 2007, Oncogene.

[100]  J. Mortimer,et al.  The receptor protein tyrosine phosphatase (RPTP)beta/zeta is expressed in different subtypes of human breast cancer. , 2007, Biochemical and biophysical research communications.

[101]  M. Grever,et al.  Methylation and Silencing of Protein Tyrosine Phosphatase Receptor Type O in Chronic Lymphocytic Leukemia , 2007, Clinical Cancer Research.

[102]  A. Scarpa,et al.  Expression of transmembrane protein tyrosine phosphatase gamma (PTPγ) in normal and neoplastic human tissues , 2007, Histopathology.

[103]  B. Neel,et al.  Protein-tyrosine phosphatase 1B is required for HER2/Neu-induced breast cancer. , 2007, Cancer research.

[104]  B. Kennedy,et al.  Protein tyrosine phosphatase 1B deficiency or inhibition delays ErbB2-induced mammary tumorigenesis and protects from lung metastasis , 2007, Nature Genetics.

[105]  B. Neel,et al.  The role of Shp2 (PTPN11) in cancer. , 2007, Current opinion in genetics & development.

[106]  G. Feng,et al.  PTPN11 is the first identified proto-oncogene that encodes a tyrosine phosphatase. , 2007, Blood.

[107]  I. Lossos,et al.  T-Cell Protein Tyrosine Phosphatase, Distinctively Expressed in Activated-B-Cell-Like Diffuse Large B-Cell Lymphomas, Is the Nuclear Phosphatase of STAT6 , 2007, Molecular and Cellular Biology.

[108]  J. Schulz,et al.  Extracellular domain splice variants of a transforming protein tyrosine phosphatase α mutant differentially activate Src‐kinase dependent focus formation , 2007, Genes to cells : devoted to molecular & cellular mechanisms.

[109]  N. Tonks,et al.  Protein tyrosine phosphatases: from genes, to function, to disease , 2006, Nature Reviews Molecular Cell Biology.

[110]  C. Chi,et al.  Protein tyrosine-phosphatase expression profiling in gastric cancer tissues. , 2006, Cancer letters.

[111]  Chunliu Zhu,et al.  Leukemia-Associated, Constitutively Active Mutants of SHP2 Protein Tyrosine Phosphatase Inhibit NF1 Transcriptional Activation by the Interferon Consensus Sequence Binding Protein , 2006, Molecular and Cellular Biology.

[112]  M. Westphal,et al.  RNA interference targeting protein tyrosine phosphatase ζ/receptor‐type protein tyrosine phosphatase β suppresses glioblastoma growth in vitro and in vivo , 2006 .

[113]  T. Naoe,et al.  PTPN11, RAS and FLT3 mutations in childhood acute lymphoblastic leukemia. , 2006, Leukemia research.

[114]  M. Noda,et al.  Protein tyrosine phosphatase receptor type Z is inactivated by ligand‐induced oligomerization , 2006, FEBS letters.

[115]  A. Ullrich,et al.  Furin-, ADAM 10-, and γ-Secretase-Mediated Cleavage of a Receptor Tyrosine Phosphatase and Regulation of β-Catenin's Transcriptional Activity , 2006, Molecular and Cellular Biology.

[116]  C. Dominici,et al.  Activating PTPN11 mutations play a minor role in pediatric and adult solid tumors. , 2006, Cancer genetics and cytogenetics.

[117]  C. Hellberg,et al.  Protein-tyrosine phosphatases and cancer , 2006, Nature Reviews Cancer.

[118]  D. Barford,et al.  PTPN11 (Shp2) Mutations in LEOPARD Syndrome Have Dominant Negative, Not Activating, Effects* , 2006, Journal of Biological Chemistry.

[119]  C. Chi,et al.  PTPN3 and PTPN4 tyrosine phosphatase expression in human gastric adenocarcinoma. , 2006, Anticancer research.

[120]  M. Tremblay,et al.  Involvement of the small protein tyrosine phosphatases TC-PTP and PTP1B in signal transduction and diseases: from diabetes, obesity to cell cycle, and cancer. , 2005, Biochimica et biophysica acta.

[121]  Su-zhan Zhang,et al.  Overexpression of Shp2 tyrosine phosphatase is implicated in leukemogenesis in adult human leukemia. , 2005, Blood.

[122]  K. Nikolich,et al.  FAS Associated Phosphatase (FAP-1) Blocks Apoptosis of Astrocytomas through Dephosphorylation of FAS , 2005, Journal of Neuro-Oncology.

[123]  G. Viglietto,et al.  The rat tyrosine phosphatase η increases cell adhesion by activating c-Src through dephosphorylation of its inhibitory phosphotyrosine residue , 2005, Oncogene.

[124]  A. Üren,et al.  PTPL1 is a direct transcriptional target of EWS-FLI1 and modulates Ewing's Sarcoma tumorigenesis , 2005, Oncogene.

[125]  J. Kutok,et al.  Prognostic, therapeutic, and mechanistic implications of a mouse model of leukemia evoked by Shp2 (PTPN11) mutations. , 2005, Cancer cell.

[126]  Heung-Chin Cheng,et al.  C-terminal Src kinase (CSK) and CSK-homologous kinase (CHK)—endogenous negative regulators of Src-family protein kinases , 2005, Growth factors.

[127]  John D. Minna,et al.  Activating Mutations of the Noonan Syndrome-Associated SHP2/PTPN11 Gene in Human Solid Tumors and Adult Acute Myelogenous Leukemia , 2004, Cancer Research.

[128]  M. Tremblay,et al.  Functional significance of the LAR receptor protein tyrosine phosphatase family in development and diseases. , 2004, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[129]  M. Loh,et al.  Functional analysis of leukemia-associated PTPN11 mutations in primary hematopoietic cells. , 2004, Blood.

[130]  G Mortier,et al.  PTPN11 mutations in patients with LEOPARD syndrome: a French multicentric experience , 2004, Journal of Medical Genetics.

[131]  M. Hatakeyama.  Oncogenic mechanisms of the Helicobacter pylori CagA protein , 2004, Nature Reviews Cancer.

[132]  D. Gilliland,et al.  Mouse model of Noonan syndrome reveals cell type– and gene dosage–dependent effects of Ptpn11 mutation , 2004, Nature Medicine.

[133]  B. Gelb,et al.  Genetic evidence for lineage-related and differentiation stage-related contribution of somatic PTPN11 mutations to leukemogenesis in childhood acute leukemia. , 2004, Blood.

[134]  Joanna M. Sasin,et al.  Protein Tyrosine Phosphatases in the Human Genome , 2004, Cell.

[135]  Giovanni Parmigiani,et al.  Mutational Analysis of the Tyrosine Phosphatome in Colorectal Cancers , 2004, Science.

[136]  M. Loh,et al.  Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis. , 2004, Blood.

[137]  M. Westphal,et al.  Expression and Function of the Receptor Protein Tyrosine Phosphatase ζ and Its Ligand Pleiotrophin in Human Astrocytomas , 2003, Journal of neuropathology and experimental neurology.

[138]  M. Westphal,et al.  A role for receptor tyrosine phosphataseζ in glioma cell migration , 2003, Oncogene.

[139]  M. Kasuga,et al.  Downregulation of stomach cancer-associated protein tyrosine phosphatase-1 (SAP-1) in advanced human hepatocellular carcinoma , 2003, Oncogene.

[140]  J. Licht,et al.  Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia , 2003, Nature Genetics.

[141]  A. Elson,et al.  Tyrosine Phosphatase-ε Activates Src and Supports the Transformed Phenotype of Neu-induced Mammary Tumor Cells* , 2003, The Journal of Biological Chemistry.

[142]  Z. Ronai,et al.  FAP-1 Association with Fas (Apo-1) Inhibits Fas Expression on the Cell Surface , 2003, Molecular and Cellular Biology.

[143]  Mitsutoshi Nakamura,et al.  Overexpression of leucocyte common antigen (LAR) P-subunit in thyroid carcinomas , 2003, British Journal of Cancer.

[144]  T. Hirayama,et al.  Mice deficient in protein tyrosine phosphatase receptor type Z are resistant to gastric ulcer induction by VacA of Helicobacter pylori , 2003, Nature Genetics.

[145]  T. Hunter,et al.  The Protein Kinase Complement of the Human Genome , 2002, Science.

[146]  Cestmir Vlcek,et al.  Ptprj is a candidate for the mouse colon-cancer susceptibility locus Scc1 and is frequently deleted in human cancers , 2002, Nature Genetics.

[147]  D. Shalloway,et al.  Mitotic Activation of Protein-tyrosine Phosphatase α and Regulation of Its Src-mediated Transforming Activity by Its Sites of Protein Kinase C Phosphorylation* , 2002, The Journal of Biological Chemistry.

[148]  B. Kennedy,et al.  Attenuation of leptin action and regulation of obesity by protein tyrosine phosphatase 1B. , 2002, Developmental cell.

[149]  Young-Bum Kim,et al.  PTP1B regulates leptin signal transduction in vivo. , 2002, Developmental cell.

[150]  Michael A. Patton,et al.  Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome , 2001, Nature Genetics.

[151]  Wei Lu,et al.  Site-specific incorporation of a phosphotyrosine mimetic reveals a role for tyrosine phosphorylation of SHP-2 in cell signaling. , 2001, Molecular cell.

[152]  H. Kalthoff,et al.  FAP-1 in pancreatic cancer cells: functional and mechanistic studies on its inhibitory role in CD95-mediated apoptosis. , 2001, Journal of cell science.

[153]  B. Kennedy,et al.  Attenuation of Adhesion-dependent Signaling and Cell Spreading in Transformed Fibroblasts Lacking Protein Tyrosine Phosphatase-1B , 2001, Journal of Biological Chemistry.

[154]  D. Scudiero,et al.  Expression and potential role of Fas-associated phosphatase-1 in ovarian cancer. , 2001, The American journal of pathology.

[155]  K. Adamsky,et al.  Glial tumor cell adhesion is mediated by binding of the FNIII domain of receptor protein tyrosine phosphatase β (RPTPβ) to tenascin C , 2001, Oncogene.

[156]  C. LeVea,et al.  PTP LAR Expression Compared to Prognostic Indices in Metastatic and Non-Metastatic Breast Cancer , 2000, Breast Cancer Research and Treatment.

[157]  S. Ménard,et al.  Expression of protein tyrosine phosphatase alpha (RPTPα) in human breast cancer correlates with low tumor grade, and inhibits tumor cell growth in vitro and in vivo , 2000, Oncogene.

[158]  Young-Bum Kim,et al.  Increased Energy Expenditure, Decreased Adiposity, and Tissue-Specific Insulin Sensitivity in Protein-Tyrosine Phosphatase 1B-Deficient Mice , 2000, Molecular and Cellular Biology.

[159]  K. Hirokawa,et al.  Expression of protein tyrosine phosphatases and its significance in esophageal cancer. , 2000, Experimental and molecular pathology.

[160]  M. Noda,et al.  Pleiotrophin signals increased tyrosine phosphorylation of β-catenin through inactivation of the intrinsic catalytic activity of the receptor-type protein tyrosine phosphatase β/ζ , 2000 .

[161]  D. Shalloway,et al.  A phosphotyrosine displacement mechanism for activation of Src by PTPα , 2000, The EMBO journal.

[162]  T. Hunter,et al.  Signaling—2000 and Beyond , 2000, Cell.

[163]  A. Elson.  Protein tyrosine phosphatase ε increases the risk of mammary hyperplasia and mammary tumors in transgenic mice , 1999, Oncogene.

[164]  U. Hellman,et al.  SHP-2 binds to Tyr763 and Tyr1009 in the PDGF β-receptor and mediates PDGF-induced activation of the Ras/MAP kinase pathway and chemotaxis , 1999, Oncogene.

[165]  Tao Yang,et al.  Leukocyte common antigen–related tyrosine phosphatase receptor: Increased expression and neuronal‐type splicing in breast cancer cells and tissue , 1999, Molecular carcinogenesis.

[166]  H. Kosmehl,et al.  Expression of the transmembrane protein tyrosine phosphatase RPTPα in human oral squamous cell carcinoma , 1999, Histochemistry and Cell Biology.

[167]  M. Noda,et al.  A receptor-like protein-tyrosine phosphatase PTPzeta/RPTPbeta binds a heparin-binding growth factor midkine. Involvement of arginine 78 of midkine in the high affinity binding to PTPzeta. , 1999, The Journal of biological chemistry.

[168]  A. Ullrich,et al.  Phosphorylation and Free Pool of β-Catenin Are Regulated by Tyrosine Kinases and Tyrosine Phosphatases during Epithelial Cell Migration* , 1999, The Journal of Biological Chemistry.

[169]  B. Kennedy,et al.  Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene. , 1999, Science.

[170]  B. Hoffman,et al.  The proto-oncogene c-myc and apoptosis , 1998, Oncogene.

[171]  G. Hannon,et al.  Protein tyrosine phosphatase PTP1B suppresses p210 bcr-abl-induced transformation of rat-1 fibroblasts and promotes differentiation of K562 cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[172]  R. U. Margolis,et al.  The Core Protein of the Chondroitin Sulfate Proteoglycan Phosphacan Is a High-affinity Ligand of Fibroblast Growth Factor-2 and Potentiates Its Mitogenic Activity* , 1998, The Journal of Biological Chemistry.

[173]  B. Franza,et al.  Protein Tyrosine Phosphatase 1B Antagonizes Signalling by Oncoprotein Tyrosine Kinase p210 bcr-abl In Vivo , 1998, Molecular and Cellular Biology.

[174]  M. Schachner,et al.  High Affinity Binding and Overlapping Localization of Neurocan and Phosphacan/Protein-tyrosine Phosphatase-ζ/β with Tenascin-R, Amphoterin, and the Heparin-binding Growth-associated Molecule* , 1998, The Journal of Biological Chemistry.

[175]  J. Yanagisawa,et al.  The Molecular Interaction of Fas and FAP-1 , 1997, The Journal of Biological Chemistry.

[176]  M. Kasuga,et al.  Overexpression of SAP-1, a transmembrane-type protein tyrosine phosphatase, in human colorectal cancers. , 1997, Biochemical and biophysical research communications.

[177]  A. Isacchi,et al.  Substitution of two variant residues in the protein tyrosine phosphatase-like PTP35/IA-2 sequence reconstitutes catalytic activity. , 1996, Biochemical and biophysical research communications.

[178]  P. Maurel,et al.  TAG-1/Axonin-1 Is a High-affinity Ligand of Neurocan, Phosphacan/Protein-tyrosine Phosphatase-ζ/β, and N-CAM* , 1996, The Journal of Biological Chemistry.

[179]  A. Elson,et al.  Protein-tyrosine Phosphatase ϵ , 1995, The Journal of Biological Chemistry.

[180]  J. Schlessinger,et al.  The carbonic anhydrase domain of receptor tyrosine phosphatase β is a functional ligand for the axonal cell recognition molecule contactin , 1995, Cell.

[181]  D. Smith,et al.  Increased mRNA expression of the receptor-like protein tyrosine phosphatase α in late stage colon carcinomas , 1995 .

[182]  John Calvin Reed,et al.  FAP-1: a protein tyrosine phosphatase that associates with Fas. , 1995, Science.

[183]  N. Tonks,et al.  Expression of DEP-1, a receptor-like protein-tyrosine-phosphatase, is enhanced with increasing cell density. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[184]  R. Bast,et al.  Overexpression of the protein tyrosine phosphatase PTP1B in human breast cancer: association with p185c-erbB-2 protein expression. , 1994, Journal of the National Cancer Institute.

[185]  J. Frangioni,et al.  Calpain‐catalyzed cleavage and subcellular relocation of protein phosphotyrosine phosphatase 1B (PTP‐1B) in human platelets. , 1993, The EMBO journal.

[186]  Xinyang Zheng,et al.  Cell transformation and activation of pp60c-src by overexpression of a protein tyrosine phosphatase , 1992, Nature.

[187]  S. Gygi,et al.  PTP1B regulates non-mitochondrial oxygen consumption via RNF213 to promote tumour survival during hypoxia , 2016 .

[188]  S. Brady-Kalnay,et al.  Regulation of development and cancer by the R2B subfamily of RPTPs and the implications of proteolysis. , 2015, Seminars in cell & developmental biology.

[189]  W. Birchmeier,et al.  The tyrosine phosphatase Shp2 in development and cancer. , 2010, Advances in cancer research.

[190]  S. Hardy,et al.  Inside the human cancer tyrosine phosphatome , 2010, Nature Reviews Cancer.

[191]  B. Gelb,et al.  Phosphatase-defective LEOPARD syndrome mutations in PTPN11 gene have gain-of-function effects during Drosophila development. , 2009, Human molecular genetics.

[192]  T. Whiteside,et al.  FAP‐1‐mediated activation of NF‐κB induces resistance of head and neck cancer to fas‐induced apoptosis , 2007, Journal of cellular biochemistry.

[193]  Andrea Richardson,et al.  A role for the scaffolding adapter GAB2 in breast cancer , 2006, Nature Medicine.